Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
72 hedge funds and large institutions have $139M invested in Synergy Pharmaceuticals, Inc Common Stock in 2013 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 17 closing their positions.
260% more call options, than puts
Call options by funds: $824K | Put options by funds: $229K
20% more capital invested
Capital invested by funds: $116M → $139M (+$23.3M)
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
6% less funds holding
Funds holding: 77 → 72 (-5)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$2.1M |
| 2 |
Renaissance Technologies
New York
|
+$912K |
| 3 |
Millennium Management
New York
|
+$617K |
| 4 |
State Street
Boston,
Massachusetts
|
+$417K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$381K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.5M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.75M |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
-$1.16M |
| 4 |
APU
Alpine Partners USVI
St. Thomas,
U.S. Virgin Islands
|
-$697K |
| 5 |
Morgan Stanley
New York
|
-$523K |
SGYP Hedge Fund Activity: Q4 2013 in Review
72 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q4 2013, worth a combined $139M — up 20% from $116M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SGYP and 12 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 25 added.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $2.1M. The largest seller was Fidelity Investments, cutting an estimated $3.5M.
- 72 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q4 2013, down from 77 in Q3 2013.
- Funds reported $139M of Synergy Pharmaceuticals, Inc Common Stock stock for Q4 2013, up 20% quarter-over-quarter.
- 12 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q4 2013 and 17 closed out, a net change of -5 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q4 2013 was Oxford Asset Management, an estimated $2.1M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q4 2013 was Fidelity Investments, an estimated $3.5M sold.
Based on aggregated 13F filings for Q4 2013.